Physician

Rawaa Ebrahem, M.D.

According to 2025 Medicare claims, Rawaa Ebrahem, M.D. (NPI: 1104206077) practices rheumatology in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is ARTHRITIS AND RHEUMATOLOGY CLINICS OF KANSAS LLC (NPI: 1700881646; TIN: 431899877) and primary practice location at 67206-3405. Ebrahem is affiliated with the Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Ebrahem's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 450 traditional Medicare patients, billed 55,430 HCPCS/CPT codes, and received $912,730 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 4,633 prescription claims across 496 beneficiaries totaling $3,835,454 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2022 DME data shows 12 claims. Open Payments data shows 58 records totaling $980. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $134,629 to $912,730. Similarly, Part D prescription costs have risen steadily, from $5,135 to $3,835,454. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	144	4,759	$134,629
2021	296	19,420	$370,673
2022	369	35,359	$539,542
2023	432	44,073	$856,541
2024	450	55,430	$912,730

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	14	56	$5,135
2016	37	146	$18,053
2017	39	322	$30,003
2018	24	136	$7,403
2019	N/R	N/R	N/R
2020	100	373	$187,348
2021	298	2,248	$2,105,030
2022	369	2,838	$2,735,421
2023	439	3,822	$3,500,784
2024	496	4,633	$3,835,454

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	12	$730
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	343	637	$10
36415	Insertion of needle into vein for collection of blood sample	330	571	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	335	624	$8
86140	Measurement c-reactive protein for detection of infection or inflammation	325	540	$5
85652	Red blood cell sedimentation rate, to detect inflammation, automated	327	542	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	156	4,368	$1,079,043
Enbrel Sureclick	Etanercept	77	2,156	$565,516
Cosentyx Sensoready Pen	Secukinumab	49	1,372	$397,467
Cosentyx Unoready Pen	Secukinumab	40	1,120	$295,966
Xeljanz Xr	Tofacitinib Citrate	48	1,438	$286,929

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	58	$980	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rawaa Ebrahem, M.D.?

Tedicare shows public-source Medicare data for Rawaa Ebrahem, M.D. (NPI 1104206077), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rawaa Ebrahem, M.D. have ACO affiliation data?

Rawaa Ebrahem, M.D. is shown with ACO affiliation data for Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Rawaa Ebrahem, M.D.?

Rawaa Ebrahem, M.D. is linked to ARTHRITIS AND RHEUMATOLOGY CLINICS OF KANSAS LLC (billing NPI 1700881646) in the available physician profile data.

Does Rawaa Ebrahem, M.D. have Open Payments data?

Rawaa Ebrahem, M.D. has 58 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.